Buscar
Mostrando ítems 1-10 de 210
5α-reductase type 3 enzyme in benign and malignant prostate
(2014-02)
BACKGROUND Currently available 5α-reductase inhibitors are not completely effective for treatment of benign prostate enlargement, prevention of prostate cancer (CaP), or treatment of advanced castration-recurrent (CR) CaP. ...
5α-reductase type 3 expression in human benign and malignant tissues : A comparative analysis during prostate cancer progression
(2011-07)
Background A third isozyme of human 5α-steroid reductase, 5α-reductase-3, was identified in prostate tissue at the mRNA level. However, the levels of 5α-reductase-3 protein expression and its cellular localization in human ...
Trypanosomatidae diseases: from the current therapy to the efficacious role of trypanothione reductase in drug discovery
(Bentham Science Publishers, 2018)
11β-hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension
(2010)
Cortisol availability is modulated by several enzymes: 11β-HSD2, which transforms cortisol (F) to cortisone (E) and 11β-HSD1 which predominantly converts inactive E to active F. Additionally, the A-ring reductases (5α- and ...
Diagnosis of 5α-reductase type 2 deficiency: Contribution of anti-Müllerian hormone evaluation
(2005-12-01)
Aim: To evaluate anti-Müllerian hormone (AMH) levels in patients with clinical and molecular diagnosis of 5α-reductase 2 deficiency. Patients and methods: Data from 14 patients whose age ranged from 21 days to 29 years ...
Diagnosis of 5α-reductase type 2 deficiency: Contribution of anti-Müllerian hormone evaluation
(2005-12-01)
Aim: To evaluate anti-Müllerian hormone (AMH) levels in patients with clinical and molecular diagnosis of 5α-reductase 2 deficiency. Patients and methods: Data from 14 patients whose age ranged from 21 days to 29 years ...
Plant tissue cultures as sources of new ene- and ketoreductase activities
(Elsevier Science, 2017-06)
While many redox enzymes are nowadays available for synthetic applications, the toolbox of ene-reductases is still limited. Consequently, the screening for these enzymes from diverse sources in the search of new biocatalyst ...